22 January 2021
Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announced
A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the treatment of schizophrenia.